GVAG
VRTX icon

Great Valley Advisor Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Great Valley Advisor Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$402K Sell
900
-7
-0.8% -$3.26K 0.01% 742
2025
Q4 		$411K Sell
907
-118
-12% -$50.9K 0.01% 686
2025
Q3 		$401K Sell
1,025
-186
-15% -$77.7K 0.01% 687
2025
Q2 		$539K Sell
1,211
-10,372
-90% -$4.78M 0.01% 583
2025
Q1 		$5.62M Sell
11,583
-9,010
-44% -$4.2M 0.12% 166
2024
Q4 		$8.29M Buy
20,593
+2,343
+13% +$1.09M 0.19% 120
2024
Q3 		$8.49M Buy
18,250
+3,463
+23% +$1.66M 0.21% 118
2024
Q2 		$6.93M Buy
14,787
+1,968
+15% +$854K 0.19% 120
2024
Q1 		$5.36M Buy
12,819
+8,737
+214% +$3.69M 0.16% 135
2023
Q4 		$1.66M Buy
4,082
+1,883
+86% +$696K 0.06% 266
2023
Q3 		$764K Buy
2,199
+594
+37% +$208K 0.03% 360
2023
Q2 		$564K Sell
1,605
-1
-0.1% -$337 0.02% 417
2023
Q1 		$506K Sell
1,606
-9,547
-86% -$2.86M 0.02% 434
2022
Q4 		$3.22M Buy
+11,153
New +$3.4M 0.16% 150
2020
Q3 		– Sell
-700
Closed -$204K – 458
2020
Q2 		$204K Buy
+700
New +$190K 0.03% 382

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Great Valley Advisor Group's VRTX Position: Q1 2026 in Review

Great Valley Advisor Group reduced its Vertex Pharmaceuticals (VRTX) stake by 0.77% in Q1 2026, selling an estimated $3.26K and leaving 900 shares worth $402K. The position accounts for 0.01% of the portfolio, ranked #742.

Great Valley Advisor Group first reported a position in VRTX in Q2 2020 and has held it in 15 quarters since. The position peaked at $8.49M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Great Valley Advisor Group held 900 shares of Vertex Pharmaceuticals worth $402K as of Q1 2026.
  • Great Valley Advisor Group sold 7 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.26K.
  • Vertex Pharmaceuticals made up 0.01% of Great Valley Advisor Group's portfolio in Q1 2026, its #742 holding.
  • Great Valley Advisor Group first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
  • Great Valley Advisor Group's Vertex Pharmaceuticals position peaked at $8.49M in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Great Valley Advisor Group's 13F filing for Q1 2026, filed 11 May 2026.